Search General Info
Search Education
Search Partnering Companies
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
Reveal is a clinical stage company positioned to transform medical insight. Our first in class imaging drugs address two major needs:
1) safer, gadolinium-free MR imaging
2) imaging fibrogenesis (PET and MRI)
Impact:
Gadolinium accumulates in the brain and body of every person using current MRI contrast agents (GBCAs); GBCAs also pollute earth's surface waters. Despite an FDA boxed warning there is no alternative for 40 million scans per year. Reveal’s RVP-001 is based on biocompatible manganese and is designed to seamlessly replace general purpose GBCAs.
Fibrotic disease contributes to 40% of US deaths but current methods cannot accurately assess early disease, active disease, or early response to treatment. Reveal’s molecular imaging agents target lysol oxidase, a byproduct of fibrogenesis, promising unprecedented insight for diagnosis, patient stratification, and early readout of response to therapy.
1) safer, gadolinium-free MR imaging
2) imaging fibrogenesis (PET and MRI)
Impact:
Gadolinium accumulates in the brain and body of every person using current MRI contrast agents (GBCAs); GBCAs also pollute earth's surface waters. Despite an FDA boxed warning there is no alternative for 40 million scans per year. Reveal’s RVP-001 is based on biocompatible manganese and is designed to seamlessly replace general purpose GBCAs.
Fibrotic disease contributes to 40% of US deaths but current methods cannot accurately assess early disease, active disease, or early response to treatment. Reveal’s molecular imaging agents target lysol oxidase, a byproduct of fibrogenesis, promising unprecedented insight for diagnosis, patient stratification, and early readout of response to therapy.
![](https://www.abstractscorecard.com/uploads/Tasks/upload/20525/EOISBJNL-1528467-1-JPG.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Tools/Drug Development Support Tech
Lead Product in Development:
RVP-001 - first gadolinium-free general purpose MRI contrast agent
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Two
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-HoffmanV.png)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved